Is fluoropyrimidindes without oxaliplatin optimal for the adjuvant treatment of mainstream stage III colon cancer?


Abali H., Yavuz S., Calikusu Z., Seyrek E.

ANNALS OF ONCOLOGY, vol.26, no.1, pp.245, 2015 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Letter
  • Volume: 26 Issue: 1
  • Publication Date: 2015
  • Doi Number: 10.1093/annonc/mdu473
  • Title of Journal : ANNALS OF ONCOLOGY
  • Page Numbers: pp.245

Abstract

This letter criticize the design of ACTS-CC trial; patients received adjuvant oral fluoropyrimidine therapy without oxaliplatin. Authors believe that oxaplatin should have been a part of the treatment in both arms.